Concetta Marsico (Italy)
IRCCS Azienda Ospedaliero Universitaria di Bologna Neonatal Intensive Care UnitAuthor Of 1 Presentation
CLINICAL AND SEROLOGICAL DATA OF NEONATES BORN TO WOMEN WITH SARS-COV-2 INFECTION IN PREGNANCY
Abstract
Backgrounds:
To evaluate the outcomes of neonates exposed to SARS-CoV-2 in pregnancy, the dynamics of maternal IgG placental transfer and its persistence during the first months of life.
Methods:
Prospective study enrolling neonates born to mothers with SARS-CoV-2 infection in pregnancy at IRCCS Azienda Ospedaliero Universitaria di Bologna, Italy, between March 2020 and September 2021. Neonates born to women with peripartum infection were excluded. All infants were enrolled in a 12-month follow-up. Quantitative IgG to S1/S2 subunits of spike protein were assessed in mother-neonates dyads within 48 hours post-delivery and during follow-up until negative. Transplacental IgG transfer ratio in relation to the trimester of maternal infection was assessed.
Results:
One hundred and forty neonates were included. No clinical, laboratory and cerebral abnormalities were detected at birth or during follow-up, until a median age of 11 months (range 6-12). Median SARS-CoV-2 S1/S2 IgG level at birth was 22 AU/mL (IQR 11-52.5) for neonates and 35 AU/mL (IQR 19-62.5) for mothers. Median IgG level at birth was not different between neonates born to asymptomatic or symptomatic mothers (18 AU/mL, IQR 9-49, versus 23.5 AU/mL, IQR 11-61.7, P=0.26) and was not different in relation to trimester of maternal infection (P= 0.9). Transplacental transfer ratio was higher following second trimester maternal infections (0.99±0.45 versus 1.05±0.61 versus 0.74±0.43, P=0.02). Maternally derived IgG were rapidly weaned: all infants had no detectable antibodies within 8 months of life.
Conclusions/Learning Points:
Neonatal and long-term outcomes of infants SARS-CoV-2 exposed in utero in all trimesters of gestation were favorable. IgG transplacental transfer was higher following second trimester maternal infections, which could be relevant to inform studies on appropriate vaccination strategies. All infants lost maternal antibodies within 8 months of life.
Presenter of 1 Presentation
CLINICAL AND SEROLOGICAL DATA OF NEONATES BORN TO WOMEN WITH SARS-COV-2 INFECTION IN PREGNANCY
Abstract
Backgrounds:
To evaluate the outcomes of neonates exposed to SARS-CoV-2 in pregnancy, the dynamics of maternal IgG placental transfer and its persistence during the first months of life.
Methods:
Prospective study enrolling neonates born to mothers with SARS-CoV-2 infection in pregnancy at IRCCS Azienda Ospedaliero Universitaria di Bologna, Italy, between March 2020 and September 2021. Neonates born to women with peripartum infection were excluded. All infants were enrolled in a 12-month follow-up. Quantitative IgG to S1/S2 subunits of spike protein were assessed in mother-neonates dyads within 48 hours post-delivery and during follow-up until negative. Transplacental IgG transfer ratio in relation to the trimester of maternal infection was assessed.
Results:
One hundred and forty neonates were included. No clinical, laboratory and cerebral abnormalities were detected at birth or during follow-up, until a median age of 11 months (range 6-12). Median SARS-CoV-2 S1/S2 IgG level at birth was 22 AU/mL (IQR 11-52.5) for neonates and 35 AU/mL (IQR 19-62.5) for mothers. Median IgG level at birth was not different between neonates born to asymptomatic or symptomatic mothers (18 AU/mL, IQR 9-49, versus 23.5 AU/mL, IQR 11-61.7, P=0.26) and was not different in relation to trimester of maternal infection (P= 0.9). Transplacental transfer ratio was higher following second trimester maternal infections (0.99±0.45 versus 1.05±0.61 versus 0.74±0.43, P=0.02). Maternally derived IgG were rapidly weaned: all infants had no detectable antibodies within 8 months of life.
Conclusions/Learning Points:
Neonatal and long-term outcomes of infants SARS-CoV-2 exposed in utero in all trimesters of gestation were favorable. IgG transplacental transfer was higher following second trimester maternal infections, which could be relevant to inform studies on appropriate vaccination strategies. All infants lost maternal antibodies within 8 months of life.